IQVIA Holdings Inc. $IQV Shares Purchased by Pinkerton Wealth LLC

Pinkerton Wealth LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 27.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,443 shares of the medical research company’s stock after purchasing an additional 4,659 shares during the quarter. Pinkerton Wealth LLC’s holdings in IQVIA were worth $4,073,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise raised its holdings in shares of IQVIA by 51.2% in the 3rd quarter. Banque Cantonale Vaudoise now owns 10,192 shares of the medical research company’s stock valued at $1,936,000 after buying an additional 3,451 shares during the period. WINTON GROUP Ltd purchased a new position in IQVIA during the 3rd quarter valued at about $3,383,000. Russell Investments Group Ltd. grew its position in IQVIA by 34.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 82,011 shares of the medical research company’s stock valued at $15,367,000 after acquiring an additional 20,901 shares in the last quarter. Private Advisor Group LLC increased its stake in IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after purchasing an additional 63 shares during the period. Finally, B. Metzler seel. Sohn & Co. AG lifted its position in shares of IQVIA by 62.4% during the third quarter. B. Metzler seel. Sohn & Co. AG now owns 32,910 shares of the medical research company’s stock worth $6,251,000 after purchasing an additional 12,642 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent research reports. Truist Financial lowered their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Jefferies Financial Group reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research report on Friday. Evercore reiterated an “outperform” rating and issued a $225.00 price objective on shares of IQVIA in a research note on Thursday, February 5th. Finally, TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the company from $174.00 to $213.00 in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Buy” and an average target price of $229.13.

IQVIA Stock Up 2.5%

Shares of IQVIA stock opened at $178.87 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a market capitalization of $30.35 billion, a P/E ratio of 22.76, a P/E/G ratio of 1.68 and a beta of 1.40. The company has a 50 day moving average of $206.26 and a 200 day moving average of $207.53.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same period in the prior year, the firm posted $3.12 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.